Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Ligandrol
Also known as: LGD-4033, VK5211
Ligandrol is a non-steroidal SARM developed by Ligand Pharmaceuticals for muscle wasting conditions. It demonstrated significant lean mass gains in Phase I trials at doses as low as 1 mg/day.
Risk Level
Medium RiskDifficulty
Intermediate| CAS Number | 1165910-22-4 |
| Molecular Formula | C14H12F6N2O |
| Class | SARM |
| Category | SARMs |
Mechanism of Action
LGD-4033 binds androgen receptors with high affinity and selectivity. It produces anabolic effects in muscle and bone while showing reduced androgenic activity in prostate tissue. Acts as a full agonist at the androgen receptor in muscle.
Dosing Research
Phase I trial used 0.1-1 mg/day. Research references commonly cite 5-10 mg/day. Half-life approximately 24-36 hours. Cycles typically 8 weeks.
Side Effects & Risks
Significant testosterone suppression even at low doses. Reduction in SHBG and total testosterone observed in clinical trials. HDL suppression. Potential liver stress at higher doses.
Research Studies
Related compounds
Ostarine
SARMOstarine is the most widely studied SARM, originally developed for muscle wasting and osteoporosis. It has completed multiple Phase II and Phase III clinical trials, making it one of the few SARMs with substantial human data.
Cardarine
OtherCardarine is not actually a SARM but a PPARδ agonist, often grouped with SARMs commercially. It was developed by GlaxoSmithKline for metabolic and cardiovascular diseases but was abandoned due to cancer findings in rodent studies.
RAD-140
SARMRAD-140 is a potent non-steroidal SARM developed by Radius Health. It has shown neuroprotective properties in preclinical studies and is currently in early clinical trials for breast cancer.
Andarine
SARMAndarine was one of the first SARMs developed by GTx Inc. It showed promise for muscle wasting and osteoporosis in preclinical trials but development was halted due to visual side effects.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.